Fresenius Kabi starts joint venture on I.V. generics in Indonesia

Fresenius Kabi has started the joint venture announced in August with the leading Indonesian pharmaceutical company PT Soho Global Health (SGH) by completing the acquisition of a 51 percent stake in PT Ethica Industri Farmasi, a subsidiary of SGH, on October 1, 2013.

The joint venture operates a production plant in Jakarta and primarily manufactures I.V. generic drugs and infusion solutions. In 2012, the product portfolio of the new joint venture generated sales of more than ?40 million.

The joint venture makes Fresenius Kabi the market leader in I.V. generics in Indonesia, and provides an attractive platform for future growth in one of the fastest-growing emerging economies in Southeast Asia.

The parties agreed not to disclose the purchase price.

Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care. In 2012, Group sales were ?19.3 billion. On June 30, 2013, the Fresenius Group had 173,325 employees worldwide.

For more information visit www.fresenius.com.

Fresenius SE
Co. KGaA
Else-Kröner-Straße 1
61346 Bad Homburg v.d.H.
Deutschland

Telefon: +49 (0) 6172 608-2302
Telefax: +49 (0) 6172 608-2294

Mail: pr-fre@fresenius.com

http://pressrelations.de/new/standard/result_main.cfm?r=546304&aktion=jour_pm